Oncolytic viruses (OVs) require viral biodistribution testing, shedding assays, genome stability sequencing, and immune profiling to advance from preclinical to clinical trials. Accelevir’s GLP OV testing CRO workflows integrate tumor immune response profiling with oncolytic virus cytokine assays for regulatory submission.
Challenges in Oncolytic Virus Development
- Viral load monitoring: Measuring replication kinetics in tumors and tissues.
- Shedding assessment: Ensuring environmental and patient safety by tracking viral presence in bodily fluids.
- Genome stability: Confirming vector integrity over multiple manufacturing lots.
- Immune profiling: Understanding both anti-tumor and anti-viral immune responses.
- BSL-2+ sample handling: Required for many OV platforms.
How Accelevir Supports OV Programs
- Viral Load Quantification
- qPCR/dPCR to measure viral genomes in tumor, blood, and other tissues.
- Time-course analysis for replication and clearance patterns.
- Shedding Studies
- Sensitive detection in urine, saliva, feces, respiratory secretions.
- GLP-compliant longitudinal monitoring.
- Genome Integrity Analysis
- Long-read sequencing for detecting mutations, deletions, or rearrangements.
- Single-viral-genome sequencing for stability tracking.
- Immune Response Profiling
- ELISpot/ICS for tumor antigen-specific and antiviral T-cell responses.
- Multiparameter flow cytometry for immune subset dynamics.
- Cytokine multiplex for inflammatory and Th1/Th2 biomarkers.
Why Partner with Accelevir
- Proven BSL-2+ workflows for infectious viral vectors.
- Integrated molecular and immunology services from one provider.
- Regulatory-ready data for IND/BLA submissions.